First Patient Treated Worldwide with the new TomoEDGE™ Dynamic Jaws Technology

First Patient Treated Worldwide with the new TomoEDGE™ Dynamic Jaws Technology

  PR Newswire

  SUNNYVALE, California, April 4, 2013

-- Heidelberg University Hospital pioneers use; providing precise and
efficient treatments

SUNNYVALE, California, April 4, 2013 /PRNewswire/ -- Accuray Incorporated
(Nasdaq: ARAY), announced today that Heidelberg University Hospital, Germany,
has treated the world's first patients with the new TomoEDGE™ Dynamic Jaws
technology combined with VoLO™ Planning as part of its TomoTherapy® System .
The new TomoEDGE Dynamic jaws technology was introduced at ASTRO 2012 as the
newest evolution to the TomoTherapy System. The managing director of the
department of radiotherapy, Jurgen Debus, M.D., and Florian Sterzing, M.D.,
radiation oncologist, both with Heidelberg University Hospital, were in charge
of these first treatments at Heidelberg University Hospital.

"We treated our first patients on March 25, 2013 using the TomoEDGE
technology, and we have successfully treated both prostate and breast
patients," said Florian Sterzing, M.D., radiation oncologist with Heidelberg
University Hospital. "With TomoEDGE we are now able to treat, faster, the
entire spectrum of the radiation oncology patients."

"With the new TomoEDGE technology, we can provide the most precise and
personalized treatment plans while also achieving significantly better dose
distributions and at the same time reduce overall treatment time," added
Jurgen Debus, medical director of the department of radiation oncology and
radiotherapy with Heidelberg University Hospital.

The new TomoEDGE technology allows for sharper dose sculpting and reduces
treatment time for many patients by approximately half, which will enable
clinics to treat more patients per day. TomoEDGE Dynamic Jaws are optimized to
open dynamically as they sweep across the target. This combines the benefits
of narrow jaw widths to better sculpt dose at the edges of the treatment
volume with larger jaw widths to complete treatment in a shorter time. The
result is a precise, yet faster and more customized treatment delivery that is
as unique as each patient.

The TomoTherapy System also includes the VoLO Technology a Graphics Processing
Unit (GPU)-based treatment planning which includes high-speed parallel
processing for both dose calculation and optimization. VoLO leverages advanced
graphics processing technology and a new calculation algorithm to
significantly reduce treatment planning time and flexibility in developing
even the most complex radiation therapy plans. Its speed allows users to
explore a range of parameter settings in a short time to maximize plan
conformality, sparing of normal tissues, and treatment efficiency.

"We are committed to our TomoTherapy users and continue to innovate to provide
the most advanced treatments in radiation oncology with the goal of improving
patient care," said Joshua H. Levine, president and chief executive officer of
Accuray. "We are proud that we have had the opportunity to collaborate with
the renowned Heidelberg University Hospital and are excited that they are the
first to see what TomoEDGE has to offer to the hospital, its physicians and
their patients. It will enable unprecedented speed and efficiency ensuring the
highest quality of care from the routine to the most complex cases."

About Heidelberg University Hospital and Department of Radiation Oncology

Internationally recognized patient care, research, and teaching - Heidelberg
University Hospital is one of the largest and most prestigious medical centers
in Germany. The Medical Faculty of Heidelberg University belongs to one of the
most internationally renowned biomedical research institutions in Europe. Both
institutions have the common goal of developing new therapies and implementing
them rapidly for patients. With about 11,000 employees, training and
qualification is an important issue. At the department of radiation oncology
and radiotherapy, the entire range of state-of-the-art radiation therapy
diagnostics and treatment is offered at the highest international level. Each
year, more than 4,000 cancer patients are treated at the department, which
offers the full range of up-to-date treatments.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments.

Safe Harbor Statement

Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited,
to clinical applications, clinical results, patient outcomes, and the
Company's leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from expectations, including risks
detailed from time to time under the heading "Risk Factors" in the company's
report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs
filed on November 8, 2012 & February 6, 2013, and as updated periodically by
our other filings. Forward-looking statements speak only as of the date the
statements are made and are based on information available to the Company at
the time those statements are made and/or management's good faith belief as of
that time with respect to future events. The Company assumes no obligation to
update forward-looking statements to reflect actual performance or results,
changes in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking
statements.

Website: http://www.accuray.com
Contact: CONTACT : Anja Kleber, Marketing Director, Europe, +
33(0)1-55-23-20-20, akleber@accuray.com, or Rebecca Phillips, Public Relations
Manager, Accuray, +1-408-716-4773, rphillips@accuray.com
 
Press spacebar to pause and continue. Press esc to stop.